AI-Enabled Drug Discovery and Clinical Trials Market
完整報告名稱與涵蓋範圍
AI-Enabled Drug Discovery and Clinical Trials Market Size, Share & Trends Analysis Report, By Application (Target Identification and Validation, Hit Discovery and Lead Optimization, Preclinical and Translational Modelling, Clinical Trial Design, Site Selection and Patient Recruitment, Trial Monitoring and Data Analysis), By Offering (Software Platforms, AI-Driven Discovery Services and Partnerships, Internally Developed Pipeline Assets), By Molecule Type (Small Molecules, Biologics, Nucleic Acid and Other Modalities), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The AI-enabled drug discovery and clinical trials market covers software platforms, discovery services and partnered programs that apply machine learning to target identification, molecule design, preclinical modelling and the design and execution of clinical trials, including site selection, patient recruitment, synthetic control arms and trial data analysis. Conventional laboratory contract research and electronic data capture systems without AI functionality are excluded.
Investment has been propelled by structure-prediction breakthroughs, large chemical and biological foundation models and the pharmaceutical industry's need to improve success rates and cut cycle times. Discovery platforms now advance internally generated candidates into clinical trials, providing early evidence on whether AI-designed molecules perform better than historical baselines, while large pharmaceutical companies sign multi-target alliances and build in-house AI teams supported by GPU infrastructure. On the clinical side, AI-driven protocol optimisation, predictive enrollment models and digital-twin control arms are being adopted to reduce trial duration and cost, with regulators issuing guidance on AI use in regulatory decision-making.
The United States dominates platform development and pharmaceutical partnering, with the United Kingdom, Switzerland and China as secondary hubs and growing adoption among Japanese and European sponsors. Competition spans AI-native biotechnology companies, computational software vendors, technology groups supplying models and infrastructure, and clinical technology providers extending into AI.
The InsightAce study supplies US$ forecasts for all application, offering, molecule type and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global AI-Enabled Drug Discovery and Clinical Trials Market Snapshot
Chapter 4. Global AI-Enabled Drug Discovery and Clinical Trials Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Application Estimates & Trend Analysis
5.1. Application & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
5.2.1. Target Identification and Validation
5.2.2. Hit Discovery and Lead Optimization
5.2.3. Preclinical and Translational Modelling
5.2.4. Clinical Trial Design, Site Selection and Patient Recruitment
5.2.5. Trial Monitoring and Data Analysis
Chapter 6. Market Segmentation 2: By Offering Estimates & Trend Analysis
6.1. Offering & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Offering:
6.2.1. Software Platforms
6.2.2. AI-Driven Discovery Services and Partnerships
6.2.3. Internally Developed Pipeline Assets
Chapter 7. Market Segmentation 3: By Molecule Type Estimates & Trend Analysis
7.1. Molecule Type & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Molecule Type:
7.2.1. Small Molecules
7.2.2. Biologics
7.2.3. Nucleic Acid and Other Modalities
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Pharmaceutical Companies
8.2.2. Biotechnology Companies
8.2.3. Contract Research Organizations
8.2.4. Academic Institutions
Chapter 9. AI-Enabled Drug Discovery and Clinical Trials Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Isomorphic Labs Limited
11.2. Recursion Pharmaceuticals, Inc.
11.3. Schrödinger, Inc.
11.4. Xaira Therapeutics, Inc.
11.5. Insitro, Inc.
11.6. Iambic Therapeutics, Inc.
11.7. Genesis Molecular AI
11.8. Insilico Medicine
11.9. NVIDIA Corporation (BioNeMo)
11.10. Medidata (Dassault Systemes)
11.11. Unlearn.AI, Inc.
11.12. Tempus AI, Inc.
11.13. Owkin, Inc.
11.14. Formation Bio, Inc.
11.15. Exscientia (Recursion)
圖表清單 List of Tables & Figures
Table 1. Global AI-Enabled Drug Discovery and Clinical Trials Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 1. Global AI-Enabled Drug Discovery and Clinical Trials Market Snapshot, 2026 & 2035
Table 2. Global AI-Enabled Drug Discovery and Clinical Trials Revenue Forecast by Offering, 2026-2035 (US$ Mn)
Figure 2. Global AI-Enabled Drug Discovery and Clinical Trials Market Share by Offering, 2026 & 2035
Table 3. Global AI-Enabled Drug Discovery and Clinical Trials Revenue Forecast by Molecule Type, 2026-2035 (US$ Mn)
Figure 3. AI Drug Discovery Value Chain from Target Identification to Clinical Trial Execution
Table 4. Global AI-Enabled Drug Discovery and Clinical Trials Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. AI-Designed Molecules in Clinical Development by Phase and Originator, 2026
Table 5. North America AI-Enabled Drug Discovery and Clinical Trials Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Growth Opportunity Analysis
Table 6. Europe AI-Enabled Drug Discovery and Clinical Trials Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Pharmaceutical Alliance and Investment Flows into AI Discovery Platforms, 2022-2026
Table 7. Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key AI-Enabled Drug Discovery and Clinical Trials Market Participants
Table 8. Latin America and Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們